Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Myeloid » Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Myeloproliferative Disorders » Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease » Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Description
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. MeSH
Hierarchy View
Subtype Terms (3)
Blast Crisis
10 drugs (7 approved, 3 experimental)
Leukemia, Myeloid, Accelerated Phase
13 drugs (10 approved, 3 experimental)
Leukemia, Myeloid, Chronic-Phase
170 drugs (105 approved, 65 experimental)
Phase 4 Indicated Drugs (1)
Phase 2 Indicated Drugs (75)
allogeneic natural killer cells
autologous cytokine induced killer cells
autologous dendritic cells electroporated with wt1 mrna
autologous mesenchymal stem cells
cord blood hematopoietic stem cell
gemtuzumab ozogamicin (mylotarg)
Phase 1 Indicated Drugs (70)
Other Experimental Indicated Drugs (6)
Organization Involved with Phase 4 Indications (40)
Organization Involved with Phase 3 Indications (72)
Accutest Research Laboratories (I) Pvt. Ltd.
Albert Einstein Israelite Hospital
Badalona Hospital Germans Trias i Pujol
Blood and Marrow Transplant Clinical Trials Network
Case Western Reserve University
Center for International Blood and Marrow Transplant Research
Central European Leukemia Study Group
National Heart, Lung, and Blood Institute (NHLBI)
Royal Liverpool & Broadgreen University Hospitals NHS Truts
Organization Involved with Phase 2 Indications (216)
Australasian Leukaemia and Lymphoma Group
Azienda Ospedaliera Universitaria Senese
Cancer and Leukemia Group B (CALGB)
Chinese Academy of Medical Sciences
City of Hope National Medical Center
Clinica Universidad de Navarra
Department of Health and Human Services
Department of Health, United Kingdom
Doris Duke Charitable Foundation
Dutch Childhood Oncology Group
European Group for Blood and Marrow Transplantation
European Organisation for Research and Treatment of Cancer
Federal University of Health Science of Porto Alegre
Federal University of Rio Grande do Sul
Fundacion CRIS de Investigación para Vencer el Cáncer
Fundación Teófilo Hernando, Spain
Herbert Irving Comprehensive Cancer Center
Hôpital Mignot, Versailles Paris
Hopital Rene Huguenin_Intitut Curie_Paris
Hospital Santa Marcelina, Sao Paulo, Brasil
Hospital Universitario Ramon y Cajal
Huazhong University of Science and Technology
Innovative Therapies For Children with Cancer Consortium
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Katholieke Universiteit Leuven
Leukaemia & Blood Cancer New Zealand
Methodist Cancer Center, Houston, Texas
National Hospital Organization, Mito Medical Center
National Institutes of Health (NIH)
New Mexico Cancer Care Alliance
Norwegian University of Science and Technology
Oregon Health and Science University
Pavlov First Saint Petersburg State Medical University
Philipps University of Marburg
Russian Academy of Medical Sciences
Shimousa Hematology Study Group
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
The Korean Society of Blood and Marrow Transplantation
The Korean Society of Hematology
The University of Texas, Dallas
The Wayne D. Kuni and Joan E. Kuni Foundation
Tokyo Metropolitan Komagome Hospital
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
University Hospital of North Norway
University of California, San Diego
University of California, San Francisco
University of Erlangen-Nuremberg
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Southern Denmark
Virginia Commonwealth University
Organization Involved with Phase 1 Indications (51)
Alex's Lemonade Stand Foundation
Arbeitsgemeinschaft medikamentoese Tumortherapie
Organization Involved with Other Experimental Indications (13)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.